Ross, D.M.Pagani, I.S.Irani, Y.D.Clarson, J.Leclercq, T.Dang, P.McLean, J.Saunders, V.A.Carne, L.Reynolds, J.Ritchie, D.S.White, D.L.Branford, S.Hughes, T.P.Yong, A.S.M.2019-07-152019-07-152019British Journal of Haematology, 2019; 186(3):e56-e600007-10481365-2141http://hdl.handle.net/2440/120083Abstract not availableen© 2019 British Society for Haematology and John Wiley & Sons Ltd.chronic myeloid leukaemiaimmunologyminimal residual diseasetreatment-free remissionLenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaJournal article003011206210.1111/bjh.158940004815012000342-s2.0-85063487180466168Ross, D.M. [0000-0001-7171-2935]Pagani, I.S. [0000-0002-3216-2966]Irani, Y.D. [0000-0002-2861-5774]White, D.L. [0000-0003-4844-333X]Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981]Hughes, T.P. [0000-0002-0910-3730] [0000-0002-7990-4509]Yong, A.S.M. [0000-0001-9452-1533]